Hong Bin Zhou

Hong Bin Zhou is currently Director at ClinChoice Medical (TIANJIN) Co., Ltd. since 2025; Director at Atour (Shanghai) Hotel Management Co., Ltd. since 2017; Director at Xinrongmao Fruit Industry Technology Group Co. Ltd. since 2019; Co-Chief Investment Officer & Managing Director at Legend Capital Co. Ltd. since 2005; Director at MicuRx Pharmaceuticals, Inc. since 2020; Non-Executive Director at Jiangsu Recbio Technology Co., Ltd. since 2021; Director at Joy Wing Mau Corp.
Ltd. since 2019; Director at Ningbo Xinwan Technology Development Co. Ltd. since 2017; Director at China Southern Airlines Cargo Logistics Guangzhou Co. Ltd. since 2021; Non-Executive Director at Shanghai Cell Therapy Group Co., Ltd. since 2023; Non-Executive Director at TriApex Laboratories Co., Ltd. since 2023; and Member-Supervisory Board at China Southern Air Logistics Co., Ltd. since 2022.
Former roles include Chairman-Supervisory Board at Shanghai Genext Medical Technology Co., Ltd.; Director at Milkyway Intelligent Supply Chain Service Group Co., Ltd. from 2015 to 2024; Director at Shanghai MicuRx Pharmaceutical Co., Ltd. from 2020 to 2024; Director at Jiangsu Lihua Food Group Co., Ltd. from 2015 to 2023; Non-Executive Director at Pharmaron Beijing Co., Ltd. from 2020 to 2023; Director at Jiangsu Lihua Animal Husbandry Co., Ltd.; Director at Chemclin Diagnostics Co., Ltd. from 2018 to 2023; Director at Atour Lifestyle Holdings Ltd.; and Member-Supervisory Board at Guangzhou Kingmed Diagnostics Group Co., Ltd. from 2015 to 2021.
Education includes a doctorate degree from Fudan University conferred in 2000, a graduate degree from Wuhan University conferred in 1997, and an undergraduate degree from Wuhan University conferred in 1994.